Tempus and the OHSU Knight Cancer Institute Collab

CHICAGO, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Tempus , a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Knight Cancer Institute at OHSU in Portland, Oregon, have announced a new collaboration aimed at improving outcomes for breast, pancreatic, and prostate cancer patients. 

As part of the initial research project, Tempus will provide molecular sequencing, analysis and decision support tools based on molecular, clinical and outcome data and patient samples provided by OHSU.   

"We are developing a new, highly personalized approach to clinical trials and working with Tempus will give us access to large datasets that will help inform our therapeutic decisions," said Christopher Corless, M.D., Ph.D., executive director and chief medical officer, Knight Diagnostic Laboratories at the OHSU Knight Cancer Institute.

"Tempus is dedicated to improving healthcare by combining vast amounts of molecular and clinical data in a system that provides real-time decision support to physicians, researchers and healthcare providers," said Eric Lefkofsky, Founder and CEO at Tempus. "We are pleased to bring our technology platform to the researchers at OHSU and look forward to working together in the pursuit of the novel therapeutic options for those fighting cancer."

The OHSU Knight Cancer Institute is the only NCI-designated Comprehensive Cancer Center between Seattle and Sacramento, a designation it has held since 1997, and recently was awarded the National Cancer Institute's highest distinction  as a Comprehensive Cancer Center. In addition to offering the latest treatments and technologies, the OHSU Knight Cancer Institute offers hundreds of research studies and clinical trials.

About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.

Clo Ewing Director of Communications at Tempus Clo@tempus.com